Quantity of eligible sufferers: CDEC mentioned the uncertainty in the volume of sufferers with moderately serious to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some sufferers who're classified as gettin